The Department of Justice is probing Baxter International Inc. as part of an investigation into whether large producers of saline solutions and other injectable medicines colluded to create supply shortages so they could benefit from higher prices.
Baxter said in a regulatory filing Thursday that it learned in April about the Justice Department criminal probe and that a federal grand jury in Pennsylvania had subpoenaed documents from the company and an unnamed employee.
Continue Reading Below
The subpoena called for Baxter to produce documents and testimony regarding the "manufacturing, selling, pricing and shortages of intravenous solutions and containers" sold by the company in addition to "communications with competitors regarding the same," the company said in a Securities and Exchange Commission filing.
Baxter wasn't immediately available for additional comment Thursday.
The Deerfield, Ill., maker of renal and hospital products has previously said it is cooperating with the New York attorney general's office in its investigation of business practices in the intravenous saline industry. It is also facing a complaint filed in federal court in Illinois regarding industry practices.
In October 2015, four U.S. senators asked the Federal Trade Commission to investigate whether companies were limiting supplies of the key hospital staple, which had seen price increases between 200% and 300% since late 2013.
At the time, Baxter said it was working to boost saline supplies and that the average U.S. selling price for a liter of its sterile saline solution had risen annually in the single- to low-double-digits on a percentage basis since 2013.
Shares of Baxter fell 0.6% to $55.65 in after-hours trading.
Write to Bowdeya Tweh at Bowdeya.Tweh@wsj.com
(END) Dow Jones Newswires
May 04, 2017 19:05 ET (23:05 GMT)